How can you ensure successful enrollment of your Phase 1 patient studies?
WCCT Global took part in a webinar which offered drug development companies strategies for overcoming the hurdles in phase 1 patient studies. The webinar was presented by WCCT’s Vice President of Early Clinical Development, Maria Apkarian.
View the recording here:
- An understanding of common models for conducting Phase 1 patient studies and the challenges present in each
- A presentation of WCCT Global’s preferred model for these types of studies, the “Sponsor-Facilitated Relationship” and instructions for implementation
- Tips for conducting proper feasibility assessments within this model
- Examples of clinical studies where the model was successfully implemented (and study functions divided effectively)
- How to best leverage the knowledge gained from early phase studies and incorporate into late stage trials
Typically, early phase studies are conducted in somewhat of an isolated fashion, evaluating safety and pharmacokinetic/pharmacodynamic data in healthy volunteers at clinical pharmacology units first. Target patient populations are occasionally incorporated into these early phase trials, with the objective of efficiently gaining insight into how the drug might perform during future testing. The issue with this model is that these Phase 1 patient studies are conducted mostly in a vacuum — at units that largely won’t be involved during Phases 2-3 — and without the oversight from the investigators who will be responsible for the patients and outpatient conduct in later stages of testing.
Incorporating patient populations into early phase studies is not a new practice, however, the current model of identifying one, or multiple, Phase 1 units with access to the patient population and conducting the study at that location still comes with many challenges. Fundamentally, Phase 1 sites don’t have access to historical records or charts to narrow down eligibility, as physician offices and late phase researchers do, and are reliant upon patient’s self-diagnosis, which leads to ineffective enrollment. While Phase 1 sites can expect a certain level of response to their marketing efforts, these may not be enough to meet the previously agreed-upon enrollment expectations and can be considerably inefficient and costly. Conversely, late phase researchers don’t have the Phase 1 unit inpatient capabilities that the project requires.
How can drug development companies overcome this hurdle? WCCT Global believes that the key to successful studies with patient populations is for sponsors to facilitate relationships between the sites hosting their early phase studies and the investigators they plan on utilizing for Phase 3. By involving late stage investigators into Phase 1 study planning and conduct, sponsor companies can achieve more successful patient enrollment, gain valuable input on future study designs based on investigator feedback, as well as identify potential risks and strategize on prevention for late stage programs. Furthermore, with this valuable information, financial investments can be better protected by producing early efficacy signals during early phase testing.
DOWNLOAD THE PRESENTATION!
This webinar presented strategies for the successful alignment of late-stage focused investigators and sites into the Phase 1 model and best practices for implementation.